Loberamisal improves functional recovery after an ischemic stroke
A new neuroprotective and neuroreparative treatment could expand therapeutic options after an acute ischemic stroke. The LAIS clinical trial has demonstrated that intravenous loberamisal, administered within the first ten days and initiated within 48 hours of symptom onset, significantly increases the proportion of patients achieving full functional recovery at 90 days. The results of the